A selective anti-TNF-α effect is desirable for developing new antirheumatic drugs, since the administration of CCL2 monoclonal antibody to patients with rheumatoid arthritis did not ameliorate the disease and even aggravated the symptoms at higher doses. The gene discussed is TNF; the disease is rheumatoid arthritis.